A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-daily Over 28 Days in Subjects With COPD.
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Umeclidinium (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 21 Jul 2012 Planned number of patients changed from 256 to 264 as reported by European Clinical Trials Database.
- 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
- 04 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.